Sökning: id:"swepub:oai:DiVA.org:uu-498007" >
Cardiovascular Risk...
Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients : A Randomized Clinical Trial
-
- Bredewold, Obbo W (författare)
- Leiden Univ, Netherlands
-
- Chan, Joe (författare)
- Akershus Univ Hosp, Norway
-
- Svensson, My (författare)
- Aalborg Univ Hosp, Denmark
-
visa fler...
-
- Bruchfeld, Annette (författare)
- Karolinska Institutet,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Njurmedicinska kliniken US,Karolinska Univ Hosp, Sweden
-
- de Fijter, Johan W (författare)
- Leiden Univ, Netherlands
-
- Furuland, Hans (författare)
- Uppsala universitet,Njurmedicin,Univ Hosp, Sweden
-
- Grinyo, Josep M (författare)
- Univ Barcelona, Spain
-
- Hartmann, Anders (författare)
- Oslo Univ Hosp, Norway
-
- Holdaas, Hallvard (författare)
- Oslo Univ Hosp, Norway
-
- Hellberg, Olof (författare)
- Orebro Univ, Sweden
-
- Jardine, Alan (författare)
- Univ Glasgow, Scotland
-
- Mjörnstedt, Lars (författare)
- Sahlgrens Univ Hosp, Sweden
-
- Skov, Karin (författare)
- Aarhus Univ Hosp, Denmark
-
- Smerud, Knut T (författare)
- Smerud Med Res Int AS, Norway
-
- Soveri, Inga (författare)
- Uppsala universitet,Njurmedicin,Univ Hosp, Sweden
-
- Sørensen, Søren S (författare)
- Copenhagen Univ Hosp, Denmark
-
- Zonneveld, Anton-Jan van (författare)
- Leiden Univ, Netherlands
-
- Fellström, Bengt, 1947- (författare)
- Uppsala universitet,Njurmedicin,Univ Hosp, Sweden
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2023
- 2023
- Engelska.
-
Ingår i: Kidney Medicine. - : Elsevier. - 2590-0595. ; 5:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- RATIONALE & OBJECTIVE: In kidney transplant recipients (KTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. Our objective was to compare the calculated CV risk between belatacept and CNI (predominantly tacrolimus) treatments using a validated model developed for KTRs.STUDY DESIGN: Prospective, randomized, open-label, parallel-group, investigator-initiated, international multicenter trial.SETTING & PARTICIPANTS: KTRs aged 18-80 years with a stable graft function (estimated glomerular filtration rate > 20 mL/min/1.73 m2), 3-60 months after transplantation, treated with tacrolimus or cyclosporine A, were eligible for inclusion.INTERVENTION: Continuation with a CNI-based regimen or switch to belatacept for 12 months.OUTCOMES: Comparison of the change in the estimated 7-year risk of major adverse CV events and all-cause mortality, changes in traditional markers of CV health, as well as measures of arterial stiffness.RESULTS: Among the 105 KTRs randomized, we found no differences between the treatment groups in the predicted risk for major adverse CV events or mortality. Diastolic blood pressure, measured both centrally by using a SphygmoCor device and peripherally, was lower after the belatacept treatment than after the CNI treatment. The mean changes in traditional cardiovascular (CV) risk factors, including kidney transplant function, were otherwise similar in both the treatment groups. The belatacept group had 4 acute rejection episodes; 2 were severe rejections, of which 1 led to graft loss.LIMITATIONS: The heterogeneous baseline estimated glomerular filtration rate and time from transplantation to trial enrollment in the participants. A limited study duration of 1 year.CONCLUSIONS: We found no effects on the calculated CV risk by switching to the belatacept treatment. Participants in the belatacept group had not only lower central and peripheral diastolic blood pressure but also a higher rejection rate.FUNDING: The trial has received a financial grant from Bristol-Myers Squibb.TRIAL REGISTRATION: EudraCT no. 2013-001178-20.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- Kidney transplantation
- arterial stiffness
- belatacept
- blood pressure
- calcineurin inhibitors
- cardiovascular disease
- mortality
- pulse wave velocity
- randomized clinical trial
- tacrolimus
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bredewold, Obbo ...
-
Chan, Joe
-
Svensson, My
-
Bruchfeld, Annet ...
-
de Fijter, Johan ...
-
Furuland, Hans
-
visa fler...
-
Grinyo, Josep M
-
Hartmann, Anders
-
Holdaas, Hallvar ...
-
Hellberg, Olof
-
Jardine, Alan
-
Mjörnstedt, Lars
-
Skov, Karin
-
Smerud, Knut T
-
Soveri, Inga
-
Sørensen, Søren ...
-
Zonneveld, Anton ...
-
Fellström, Bengt ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Kidney Medicine
- Av lärosätet
-
Uppsala universitet
-
Linköpings universitet
-
Karolinska Institutet